NDAORALTABLETPriority Review
Approved
May 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
CYTOMEL (liothyronine sodium) by Pfizer is synthesis. First approved in 1956.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYTOMEL (liothyronine sodium) is a synthetic form of triiodothyronine (T3), a thyroid hormone replacement used to treat hypothyroidism and myxedema. The drug works by binding to thyroid receptor proteins in the cell nucleus, activating gene transcription and restoring metabolic function. T3 is the physiologically active form of thyroid hormone, responsible for ~80% of thyroid hormone effects.
$2.0MPart D
LOE ApproachingStable
A legacy product in late-stage lifecycle with modest Part D volume signals a small, maintenance-focused commercial team focused on patient retention rather than growth.
Mechanism of Action
synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)
Started Oct 2007
31 enrolled
Healthy
Career Relevance
CYTOMEL represents a mature-stage career opportunity best suited for professionals comfortable with stable, lower-growth portfolios and focused on operational excellence rather than launching innovation. Working on this product emphasizes deep customer relationships, market access strategy, and defending market share against generics and therapeutic alternatives.
Brand Manager
Worked on CYTOMEL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.